title: Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients.
abstract: Circulating adiponectin (ADP) level in diabetic patients was mainly studied from a viewpoint of insulin action, with little being known about the regulation by pancreatic beta-cell function. We thus investigated the relationship between the serum ADP concentration and pancreatic beta-cell function in non-obese [body mass index (BMI) <30 kg/m(2)] diabetic patients. Serum ADP was measured in 239 type 2 diabetic patients, 61 type 1 diabetic patients and 159 non-obese and non-diabetic subjects with enzyme-linked immunosorbent assay. Serum ADP was analyzed separately by gender. In both males and females, the ADP level increased in conjugation with beta-cell dysfunction, estimated by fasting serum C-peptide, and showed marked increase in type 1 diabetic patients. Multivariate analysis in type 2 diabetic patients showed that the fasting serum C-peptide was extracted as an independent and significantly negative modulator for serum ADP in addition to BMI. The ADP level was not associated with the daily dose of injected insulin in the multivariate analysis using insulin treated patients with types 1 and 2 diabetes. These results indicate that pancreatic beta-cell function is one of a significant negative modulator for the circulating ADP level in non-obese diabetic patients and support the presence of an adipoinsular axis.
authors.affiliation: Department of Clinical Laboratory Medicine, Wakayama Medical University, Japan.
authors.forename: Machi
authors.initials: M
authors.lastname: Furuta
authors.forename: Masanori
authors.initials: M
authors.lastname: Tamai
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hanabusa
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Kishio
authors.initials: K
authors.lastname: Nanjo
authors.forename: Tokio
authors.initials: T
authors.lastname: Sanke
mesh_terms: D052242:Adiponectin / Q000097:blood; D050154:Adiposity / Q000502:physiology; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood*; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D005215:Fasting / Q000097:blood*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells / Q000502:physiology; D008297:Male; D009765:Obesity / Q000097:blood; D012044:Regression Analysis; D012727:Sex Characteristics; D013223:Statistics as Topic
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin